The HOYA MiYOSMART was the first of the new generation of myopia control spectacle lenses, with evidence for slowing myopia progression by at least half. Learn more about efficacy, the lens design, visual outcomes and more.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
The MiSight 1 day clinical trial is the longest-running soft contact lens study among children, and is now reporting seven-year data. With questions explored including efficacy, cross over from control group to treatment and discontinuation, here’s some of what we’ve learnt along the way.
The first year data from the ongoing CYPRESS randomized clinical trial show that Diffusion Optics Technology (DOT) spectacle lenses can regulate contrast signals across the retina to reduce myopia progression in children aged 6-10 years, and are safe and effective to wear.
The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
Dr Carolyn Lederman, ophthalmologist from the United States, explains how she prescribes and manages myopia patients with the NaturalVue Multifocal 1 Day contact lens in her practice.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
This retrospective cohort analysis showed that NaturalVue Multifocal 1 Day contact lens wear appears to result in a mean refractive myopia progression of less than 0.25D per year, based on available data. Some limited axial length data was also presented.
In this case, a colleague has his first experience with the new Essilor Stellest spectacle lens for childhood myopia, with discussion including when to change the prescription and when to stop treatment.
